Pfizer and Astellas report positive Phase III data from prostate cancer trial

Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news